Aura Biosciences Inc. (AURA)
NASDAQ: AURAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AURA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $714.99M
- EPS (TTM)
- -$1.59
- Dividend yield
- None
- 52-week range
- 4.73 – 9.54
- Day range
- 6.51 – 6.97
- Volume / Avg
- 791.13K / 847.22K
- Beta
- —
- Shares outstanding
- 104.07M
52-week range
AURA stock today
Aura Biosciences (AURA) closed at $6.87 on Nov 20, down 1.58% (-$0.11), versus the S&P 500's 3.70% decline. Shares are 27.9% below their 52-week high of $9.54, set on May 5, 2026 and 45.2% above the 52-week low of $4.73, in the middle of the past year's range. AURA is up 26.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 26.3%.
Aura Biosciences has posted a net loss over the last twelve months (EPS of -$1.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aura Biosciences
Company profileAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Ms. Natalie C. Holles
- Headquarters
- Boston, MA
- Employees
- 113
- IPO year
- 2021
- Website
- aurabiosciences.com
Financial highlights
Full financialsAura Biosciences reported a net loss of $106.2 million, compared with a loss of $86.9 million a year earlier. Diluted earnings per share came in at -$1.76.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-106.19M | $-86.92M | $-76.41M | $-58.76M | $-35.25M |
| EPS (diluted) | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-8.95 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$16.60+141.63%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.29 vs $-0.31
- Surprise
- +6.45%
AURA news
All AURA news- OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidateGlobeNewswire
- Oxford Biomedica Confirms Aura Biosciences Partnership For Phase 3 Eye Cancer Drug ManufacturingNasdaq
- Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNasdaq
- Aura Biosciences GAAP EPS of -$0.29Seeking Alpha
- Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire
- Aura Biosciences to Participate in Upcoming Investor ConferenceGlobeNewswire
Aura Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs AURA |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs AURA |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs AURA |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs AURA |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs AURA |
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs AURA |
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs AURA |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs AURA |
Indexes, lists and sector
Aura Biosciences stock FAQ
What is Aura Biosciences's stock price today?
AURA last traded at $6.87 as of Nov 20, 4:00 PM EST, down 1.58% on the day. Prices are delayed at least 15 minutes.
Who is Aura Biosciences's CEO?
Ms. Natalie C. Holles is the chief executive officer of Aura Biosciences Inc., which has about 113 employees.
What is the AURA 52-week high?
The 52-week high for AURA is $9.54 and the 52-week low is $4.73. The stock is currently 27.9% below its high.